NCT03336502View on ClinicalTrials.gov

Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

November 26, 2018

Study Completion Date

November 26, 2018

Conditions
Fungal Infection
Interventions
DRUG

Posaconazole

Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension

Trial Locations (7)

100044

Peking University People's Hospital ( Site 0008), Beijing

100191

Peking University Third Hospital ( Site 0009), Beijing

100730

Peking Union Medical College Hospital ( Site 0006), Beijing

200080

Shanghai General Hospital ( Site 0007), Shanghai

215006

The First Affiliated Hospital of Soochow University ( Site 0004), Suzhou

300020

Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 0001), Tianjin

510080

Guangdong General Hospital, Guangdong Academy of Medical Science ( Site 0002), Guangzhou

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03336502 - Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120) | Biotech Hunter | Biotech Hunter